Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax

Chronic lymphocytic leukemia (CLL) is a hematological neoplasm of CD19-positive mature-appearing B lymphocytes. Despite the clinical success of targeted therapies in CLL, the development of resistance diminishes their therapeutic activity. This is also true for the Bcl-2 antagonist venetoclax. We in...

Descripción completa

Detalles Bibliográficos
Autores principales: Avsec, Damjan, Škrlj Miklavčič, Marja, Burnik, Tilen, Kandušer, Maša, Bizjak, Maruša, Podgornik, Helena, Mlinarič-Raščan, Irena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547871/
https://www.ncbi.nlm.nih.gov/pubmed/36209148
http://dx.doi.org/10.1038/s41419-022-05287-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547871/
https://www.ncbi.nlm.nih.gov/pubmed/36209148
http://dx.doi.org/10.1038/s41419-022-05287-6

Ejemplares similares